Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Revises Zoloft Ad After FDA Cites Lack Of Suicide Information

Executive Summary

Pfizer is revising Zoloft (sertraline) advertisements after FDA cited the company for not incorporating updated risk information in a print ad for the antidepressant

You may also be interested in...



FDA Ad Warning Letters On Track For Significant Increase In 2005

FDA is on track for a significant increase in the number of warning letters issued to drug marketers for advertising violations in 2005

FDA Ad Warning Letters On Track For Significant Increase In 2005

FDA is on track for a significant increase in the number of warning letters issued to drug marketers for advertising violations in 2005

FDA Challenges Four Rx Ads; TAP Decides To Suspend Prevacid TV Campaign

TAP's decision to suspend Prevacid TV commercials could be an early indication of a decline in broadcast advertising for pharmaceutical products

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel